Ionis (IONS) Q2 2026 earnings review
Commercial Transition Hits a Bumpy Road
Ionis's Q2 results present a highly polarized narrative. On the commercial front, the planned pricing reset for TRYNGOLZA resulted in an 81% sequential revenue collapse to just $5M. However, this was the necessary cost to unlock its recent FDA approval for the massive sHTG market. Meanwhile, DAWNZERA is successfully accelerating, up 63% sequentially. The most significant negative development occurred in the pipeline: the highly anticipated Phase 3 CARDIO-TTRansform trial for eplontersen missed its primary composite endpoint in the overall population, dealing a severe blow to a key pillar of the company's long-term growth thesis.
🐂 Bull Case
TRYNGOLZA is now approved for severe hypertriglyceridemia (sHTG). With the Q2 pricing pain behind them, the drug is positioned to attack a multi-billion dollar TAM starting in Q3.
DAWNZERA (HAE) is demonstrating excellent market traction, growing 63% sequentially to $26M, proving Ionis's ability to execute in competitive switch markets.
🐻 Bear Case
Eplontersen missed the primary composite endpoint in the overall population for ATTR-CM. This heavily damages the narrative that the 'silencer class' will automatically dominate the cardiomyopathy market.
While a Q2 dip was telegraphed, an 81% sequential drop to $5M highlights extreme gross-to-net sensitivity. Hitting the $100-$110M FY guidance now requires a massive, flawless H2 ramp.
⚖️ Verdict: ⚪
Neutral. The underlying commercial base is strengthening with DAWNZERA's success and TRYNGOLZA's label expansion, but the clinical miss in ATTR-CM removes a massive future value driver that was highly anticipated by the market.
Key Themes
Major Clinical Miss Contradicts Bullish Narrative
In Q1, management confidently stated their belief that the 'silencer class will end up being the mechanism of choice' for ATTR-CM. Q2 data aggressively contradicted this: the Phase 3 CARDIO-TTRansform study missed the primary composite endpoint in the overall population. While it showed 'nominal significance' in the monotherapy subgroup, the broader failure significantly degrades the commercial ceiling for eplontersen against entrenched competitors like Pfizer's Vyndaqel/Vyndamax and emerging generics.
TRYNGOLZA's Pricing Cliff
Reversing. TRYNGOLZA sales collapsed from $27M in 26Q1 to just $5M in 26Q2. Management deliberately reset the WAC price to $40,000 effective April 1 to align with 2027 payer contracting cycles ahead of the sHTG launch. While expected, the magnitude of the 81% sequential drop exposes the severe short-term gross-to-net concessions required to secure long-term formulary access.
DAWNZERA Execution in a Switch Market
Accelerating. DAWNZERA continues to exceed expectations, posting $26M in Q2 (up 63% QoQ). The HAE market is highly competitive and heavily reliant on switching patients off existing prophylaxis. The rapid revenue ramp validates the drug's patient-friendly profile (room temperature storage, auto-injector) and proves Ionis's commercial infrastructure is highly functional.
sHTG Approval Unlocks the TAM
TRYNGOLZA officially received FDA approval in late June as the first and only treatment to reduce triglycerides and acute pancreatitis risk in adults with sHTG. This transitions the drug from an ultra-rare FCS indication (~3,000 patients) to a broad market of over 1 million U.S. patients. With the pricing reset complete, this is the company's primary growth engine for H2 2026.
Rich Partner Milestones Mitigate Cash Burn
Stable. While non-GAAP operating loss was $57M in Q2, this was heavily subsidized by $133M in collaborative agreement revenue. Upcoming catalysts, including the October PDUFA date for bepirovirsen (GSK) targeting functional cures in Hepatitis B, ensure a steady flow of non-dilutive capital to fund the internal commercial buildout.
Expense Base Elevated for Launch Prep
GAAP Operating expenses hit $370M in Q2, up 19% YoY. While management notes this is 'in line with expectations,' the company is concurrently funding the sHTG launch, the ongoing DAWNZERA ramp, and pre-commercial work for zilganersen (PDUFA Sept 22). If revenue ramps lag expectations, this high fixed cost base will rapidly compress the timeline to cash-flow breakeven.
Other KPIs
Accelerating slightly on a net basis. Despite TRYNGOLZA's $22M sequential drop, total product sales increased from $19M in 25Q2 to $31M in 26Q2, supported entirely by the addition of DAWNZERA and other commercial revenue. This diversification is critical for stabilizing the top line.
Stable. SPINRAZA remains a highly resilient cash cow, generating $402M in global sales for Biogen and returning $53M to Ionis, essentially flat compared to $54M a year ago.
Down from $2.7B at year-end 2025. The decrease was primarily driven by the scheduled repayment of the $633M 0% convertible notes on April 1, 2026. The balance sheet remains sufficiently capitalized to support the 2028 cash-flow breakeven goal.
Guidance
Stable. Management reiterated the full-year guidance. Adjusting for the one-time $280M sapablursen upfront payment from 2025, this implies approximately 20% YoY top-line growth. Achievement relies heavily on a strong H2 commercial ramp and late-year milestone payments.
Accelerating. With $32M generated in H1, guidance implies $68-$78M in H2. This requires sHTG volume to immediately overwhelm the severe Q2 pricing reset.
Accelerating. With $42M logged in H1, guidance implies $68-$78M in H2. Given the $26M achieved in Q2 alone, this guidance appears highly achievable, and potentially conservative, if current switch momentum persists.
Key Questions
CARDIO-TTRansform Miss Diagnostics
Given the miss on the primary composite endpoint in the overall population, what specific components of the composite drove the failure, and does the nominal significance in the monotherapy subgroup provide a viable regulatory path forward?
TRYNGOLZA Gross-to-Net Stabilization
With the WAC price reset to $40,000 implemented on April 1 resulting in just $5M in Q2 net sales, at what point in H2 do you expect gross-to-net dynamics to stabilize, and what is the assumed net price underpinning your $100-$110M annual guidance?
DAWNZERA Sustained Momentum
DAWNZERA achieved a massive 63% sequential growth rate. What percentage of these Q2 starts were treatment-naive versus switches, and are you seeing competitive retaliation in the form of increased rebating from existing HAE prophylactic market leaders?